Segall Bryant & Hamill LLC bought a new stake in PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 100,801 shares of the company's stock, valued at approximately $8,076,000. Segall Bryant & Hamill LLC owned about 0.19% of PROCEPT BioRobotics at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently made changes to their positions in the company. Sei Investments Co. grew its position in PROCEPT BioRobotics by 35.9% during the first quarter. Sei Investments Co. now owns 22,777 shares of the company's stock worth $1,126,000 after buying an additional 6,011 shares in the last quarter. ProShare Advisors LLC grew its position in PROCEPT BioRobotics by 8.5% during the first quarter. ProShare Advisors LLC now owns 7,250 shares of the company's stock worth $358,000 after buying an additional 570 shares in the last quarter. Vanguard Group Inc. grew its position in PROCEPT BioRobotics by 1.5% during the first quarter. Vanguard Group Inc. now owns 4,246,749 shares of the company's stock worth $209,874,000 after buying an additional 62,164 shares in the last quarter. Bellevue Group AG grew its position in PROCEPT BioRobotics by 0.5% during the first quarter. Bellevue Group AG now owns 890,114 shares of the company's stock worth $43,989,000 after buying an additional 4,768 shares in the last quarter. Finally, Castleark Management LLC acquired a new stake in PROCEPT BioRobotics during the first quarter worth approximately $2,841,000. Institutional investors and hedge funds own 89.46% of the company's stock.
Insider Buying and Selling
In other news, CFO Kevin Waters sold 25,000 shares of PROCEPT BioRobotics stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $72.47, for a total value of $1,811,750.00. Following the completion of the transaction, the chief financial officer now directly owns 96,096 shares of the company's stock, valued at approximately $6,964,077.12. This trade represents a 20.64 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Antal Rohit Desai sold 35,220 shares of PROCEPT BioRobotics stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $76.12, for a total value of $2,680,946.40. Following the completion of the transaction, the director now directly owns 23,963 shares of the company's stock, valued at approximately $1,824,063.56. This trade represents a 59.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 561,773 shares of company stock valued at $49,073,125 in the last three months. Insiders own 17.40% of the company's stock.
PROCEPT BioRobotics Price Performance
Shares of PRCT traded down $0.85 during trading hours on Friday, reaching $93.60. The stock had a trading volume of 361,207 shares, compared to its average volume of 657,436. PROCEPT BioRobotics Co. has a 12 month low of $33.45 and a 12 month high of $103.81. The stock has a market capitalization of $4.88 billion, a PE ratio of -48.71 and a beta of 1.01. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.07 and a current ratio of 6.02. The company's 50-day moving average is $82.16 and its two-hundred day moving average is $72.24.
PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last announced its quarterly earnings results on Monday, October 28th. The company reported ($0.40) EPS for the quarter, beating analysts' consensus estimates of ($0.49) by $0.09. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. The company had revenue of $58.40 million during the quarter, compared to analysts' expectations of $53.30 million. During the same period in the prior year, the company earned ($0.51) EPS. PROCEPT BioRobotics's revenue was up 66.4% compared to the same quarter last year. Research analysts expect that PROCEPT BioRobotics Co. will post -1.74 EPS for the current year.
Analysts Set New Price Targets
A number of equities research analysts have weighed in on the company. Piper Sandler reaffirmed an "overweight" rating and issued a $75.00 target price on shares of PROCEPT BioRobotics in a report on Tuesday, October 8th. Wells Fargo & Company raised their target price on PROCEPT BioRobotics from $67.00 to $69.00 and gave the company an "overweight" rating in a report on Friday, August 2nd. TD Cowen raised their target price on PROCEPT BioRobotics from $75.00 to $99.00 and gave the company a "buy" rating in a report on Monday, September 16th. Truist Financial reaffirmed a "buy" rating and issued a $105.00 target price (up previously from $95.00) on shares of PROCEPT BioRobotics in a report on Wednesday, October 30th. Finally, Jefferies Financial Group assumed coverage on PROCEPT BioRobotics in a report on Thursday, November 14th. They issued a "hold" rating and a $95.00 target price on the stock. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $89.50.
Get Our Latest Analysis on PRCT
PROCEPT BioRobotics Profile
(
Free Report)
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).
Further Reading
Before you consider PROCEPT BioRobotics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PROCEPT BioRobotics wasn't on the list.
While PROCEPT BioRobotics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.